ClinicalTrials.gg
RecruitingNCT07388771Updated Mar 19, 2026

Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer(NSCLC)

An observational study in NSCLC and Neoadjuvant Therapy, sponsored by Qian Chu. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Qian Chu · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

This observational study aims to construct and validate the performance of a multimodal predictive model in forecasting the outcomes of neoadjuvant therapy in patients with NSCLC.

The core research question is: Can a multi-model approach predict outcomes of neoadjuvant therapy for non-small cell lung cancer and provide clinical recommendations?

02

Conditions studied

  • NSCLC
  • Neoadjuvant Therapy
03

In context

Lead sponsor

Qian Chu is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

NSCLC patients suitable for neoadjuvant therapy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. diagnosed non-small cell lung cancer
  2. The treatment plan is:receiving chemo-immunotherapy during the study period, followed by surgical resection

Exclusion criteria

Exclusion Criteria:

  1. recurrent or lung cancer;
  2. patients with other primary tumors
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • NSCLC with neoadjuvant therapy but without surgery
  • NSCLC with neoadjuvant therapy and surgery
06

What researchers measure

Primary outcomes

  1. pathologic response

    Time frame: Perioperative

Secondary outcomes

  1. EFS

    event free survival

    Time frame: One year after the treatment ended

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Due to patient and hospital ethical requirements, this project does not currently meet the criteria for Individual Patient Data (IPD).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Oct 2026, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 5, 2026
StartActual
Dec 1, 2025
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2026
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07388771
Lead sponsor
Qian Chu
Responsible party
Qian Chu (Director of the Thoracic Oncology Department, Tongji Hospital) — Sponsor-investigator
First posted
Feb 5, 2026
Start date
Dec 1, 2025
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Mar 19, 2026

Study contacts

Minghao Hu
Contact
huminghao2010@126.com
8613396366466

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion